Earnings History Data for Seagen Inc. (SGEN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Seagen Inc.

Seagen Inc. is a biotechnology company. It discovers, develops and commercializes transformative cancer medicines. The company operates principally in California, Canada, Switzerland and the European Union. Seagen Inc., formerly known as Seattle Genetics Inc., is headquartered in the Seattle.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
01-11-2023	PM		SGEN	Seagen Inc.	40,200	-1.15	-0.71	-1.03	Seattle Genetics GAAP EPS of -$1.15 misses by $0.37, revenue of $571M misses by $64.1M [11/1/2023 8:03 AM]	214.36	1.55 (0.73%)	213.00	0.19 (0.09%)	116.08 - 217.51	1,021,479	1,470,000	15,194
Pfizer CEO expects Seagen deal to close before year end, or early in 2024 [10/31/2023 4:17 PM] Seattle Genetics Q3 2023 Earnings Preview [10/31/2023 3:17 PM] Seagen GAAP EPS of -$1.15 misses by $0.37, revenue of $571M misses by $64.1M [11/1/2023 8:03 AM]
02-08-2023	PM		SGEN	Seagen Inc.	35,960	-1.13	-0.78	-0.73	Seattle Genetics GAAP EPS of -$1.13 misses by $0.31, revenue of $603.8M beats by $45.21M [8/2/2023 8:16 AM]	193.03	0.58 (0.30%)	195.00	2.55 (1.33%)	116.08 - 207.16	524,681	1,110,000	355
Seattle Genetics Q2 2023 Earnings Preview [8/1/2023 11:18 AM] Seattle Genetics GAAP EPS of -$1.13 misses by $0.31, revenue of $603.8M beats by $45.21M [8/2/2023 8:16 AM]
27-04-2023	AH	4:00 PM ET (Apr 27)	SGEN	Seagen Inc.	38,060	-0.93	-0.82	-0.74		200.14	-0.62 (-0.31%)	201.10	0.34 (0.17%)	105.43 - 207.16	1,342,654	1,320,000	1,016

15-02-2023	AH	4:00 PM ET (Feb 15)	SGEN	Seagen Inc.	25,140	-0.80	-1.02	-0.95	Seattle Genetics GAAP EPS of -$0.80 beats by $0.25, revenue of $528M beats by $48.19M [2/15/2023 4:03 PM]	160.71	18.66 (13.14%)	152.02	9.97 (7.02%)	105.43 - 183.00	4,166,891	780,000	107,581
Seattle Genetics GAAP EPS of -$0.80 beats by $0.25, revenue of $528M beats by $48.19M [2/15/2023 4:03 PM] Seagen up 6% on quarterly beats, though 2023 revenue outlook comes in below consensus [2/15/2023 6:33 PM] Seagen nears six-month high as Wall Street cheers Q4 results [2/16/2023 3:24 PM]
27-10-2022	AH	4:00 PM ET (Oct 27)	SGEN	Seagen Inc.	23,750	-1.03	-0.92	-1.61	Seattle Genetics GAAP EPS of -$1.03 misses by $0.07, revenue of $510.3M beats by $49.29M [10/27/2022 4:11 PM]	129.80	-1.45 (-1.10%)	130.00	-1.25 (-0.95%)	105.43 - 192.79	1,350,675	980,000	4,148
Seattle Genetics GAAP EPS of -$1.03 misses by $0.07, revenue of $510.3M beats by $49.29M [10/27/2022 4:11 PM] Seagen Reports Third Quarter 2022 Financial Results [Oct-27-22 04:02PM] Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates [Oct-27-22 05:25PM]
28-07-2022	AH	4:00 PM ET (Jul 28)	SGEN	Seagen Inc.	31,590	-0.73	-0.82	-0.47	Seattle Genetics GAAP EPS of -$0.73 beats by $0.13, revenue of $497.5M beats by $59.73M [7/28/2022 4:05 PM]	179.96	2.53 (1.43%)	175.50	-1.93 (-1.09%)	105.43 - 192.79	911,934	990,000	25,721
Seattle Genetics GAAP EPS of -$0.73 beats by $0.13, revenue of $497.5M beats by $59.73M [7/28/2022 4:05 PM] Seagen 2022 revenue guidance in range as Q2 net loss widens [7/28/2022 5:47 PM] Merck Tops Profit Estimates on Strong Keytruda and Gardasil Sales [Jul-28-22 06:44AM] Seagen Reports Second Quarter 2022 Financial Results [Jul-28-22 04:02PM] Predicting the Next FDA Juul Crackdown and More: Join Stream and Sentieo Thursday in Fireside to Discuss Expert Call Platform [Jul-28-22 12:28PM]
28-04-2022	AH	4:00 PM ET (Apr 28)	SGEN	Seagen Inc.	24,190	-0.74	-0.98	-0.67	Seattle Genetics GAAP EPS of -$0.74 beats by $0.26, revenue of $426.46M beats by $24.71M [4/28/2022 4:08 PM]	131.12	0.89 (0.68%)	130.60	0.37 (0.28%)	117.46 - 192.79	1,140,946	820,000	25,163
Seattle Genetics GAAP EPS of -$0.74 beats by $0.26, revenue of $426.46M beats by $24.71M [4/28/2022 4:08 PM] Seagen Q1 earnings beats estimates, co posts rev growth across all four cancer therapies [4/28/2022 6:03 PM] Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting [Apr-28-22 08:00AM] Seagen Reports First Quarter 2022 Financial Results [Apr-28-22 04:02PM] Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates [Apr-28-22 05:45PM]
09-02-2022	AH	4:00 PM ET (Feb 9)	SGEN	Seagen Inc.	25,220	-0.95	-0.76	0.90	Seattle Genetics GAAP EPS of -$0.95 misses by $0.11, revenue of $429.9M beats by $28.23M [2/9/2022 4:05 PM]	124.22	-17.18 (-12.15%)	121.76	-19.65 (-13.90%)	118.00 - 192.79	8,508,358	1,060,000	280,836
Seattle Genetics GAAP EPS of -$0.95 misses by $0.11, revenue of $429.9M beats by $28.23M [2/9/2022 4:05 PM] Seagen sets 2022 guidance below expectations despite Q4 revenue beat [2/9/2022 4:30 PM] Sivik Global Healthcare LLC Buys SPDR Biotech ETF, Anthem Inc, Universal Health Services Inc, ... [Feb-08-22 09:38AM] Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference [Feb-08-22 08:00AM] Seagen Reports Fourth Quarter and Full Year 2021 Financial Results [Feb-09-22 04:02PM] Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates [Feb-09-22 05:15PM]
28-10-2021	AH	4:00 PM ET (Oct 28)	SGEN	Seagen Inc.	32,330	-1.61	-0.56	3.50	Seattle Genetics EPS misses by $1.04, beats on revenue [10/28/2021 4:07 PM]	176.60	-1.19 (-0.67%)	179.58	1.79 (1.01%)	133.20 - 202.60	1,041,647	580,000	8,099
Seattle Genetics EPS misses by $1.04, beats on revenue [10/28/2021 4:07 PM] Seagen raises full-year revenues estimates as Q3 net product sales increase 37% YoY [10/28/2021 5:02 PM] Seagen Reports Third Quarter 2021 Financial Results [Oct-28-21 04:02PM] Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates [Oct-28-21 05:45PM] Seattle Genetics (SGEN) Q3 2021 Earnings Call Transcript [Oct-29-21 07:01AM]
29-07-2021	AH	4:00 PM ET (Jul 29)	SGEN	Seagen Inc.	26,210	-0.47	-0.61	-0.54	Seattle Genetics EPS beats by $0.13, beats on revenue [7/29/2021 4:10 PM]	153.37	6.42 (4.37%)	151.00	4.05 (2.76%)	133.20 - 213.94	1,262,987	830,000	6,204
Seattle Genetics EPS beats by $0.13, beats on revenue [7/29/2021 4:10 PM] Seagen shares rise after Q2 earnings beat [7/29/2021 4:29 PM] Seagen Reports Second Quarter 2021 Financial Results [Jul-29-21 04:02PM] Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates [Jul-29-21 05:25PM] Seattle Genetics (SGEN) Q2 2021 Earnings Call Transcript [Jul-30-21 10:03AM]
29-04-2021	AH	4:00 PM ET (Apr 29)	SGEN	Seagen Inc.	26,740	-0.67	-0.59	-0.64	Seattle Genetics EPS misses by $0.06, misses on revenue; reaffirms FY2021 guidance [4/29/2021 4:04 PM]	143.77	4.54 (3.26%)	136.51	-2.72 (-1.95%)	134.10 - 213.94	1,239,890	840,000	16,784
Seattle Genetics EPS misses by $0.06, misses on revenue; reaffirms FY2021 guidance [4/29/2021 4:04 PM] Despite 52% rise in product sales, SeaGen misses Q1 earnings estimates [4/29/2021 5:32 PM] Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting [Apr-29-21 08:00AM] Seagen Inc. to Host Earnings Call [Apr-29-21 02:30PM] Seagen Reports First Quarter 2021 Financial Results [Apr-29-21 04:02PM] Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates [Apr-29-21 05:25PM] Seattle Genetics (SGEN) Q1 2021 Earnings Call Transcript [Apr-30-21 03:01AM]
11-02-2021	AH	4:00 PM ET (Feb 11)	SGEN	Seagen Inc.	31,710	0.90	0.81	-0.22	Seattle Genetics EPS beats by $0.04, beats on revenue [2/11/2021 4:06 PM]	165.03	-6.99 (-4.06%)	163.00	-9.02 (-5.24%)	90.57 - 213.94	2,749,846	1,380,108	8,179
Seattle Genetics EPS beats by $0.04, beats on revenue [2/11/2021 4:06 PM] Seagen’s Tukysa wins European approval for breast cancer [2/12/2021 7:45 AM] Seagen/Astella announce data showing survival advantage of PADCEV in bladder cancer [2/12/2021 3:15 PM] Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy [Feb-12-21 02:15PM] Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer [Feb-12-21 02:15PM] Seattle Genetics (SGEN) Q4 2020 Earnings Call Transcript [Feb-12-21 05:31AM] Seattle Genetics (SGEN) Q4 Earnings and Revenues Top Estimates [Feb-11-21 05:45PM] Seagen Inc. to Host Earnings Call [Feb-11-21 02:30PM]
29-10-2020	AH	4:00 PM ET (Oct 29)	SGEN	Seagen Inc.	34,260	3.50	-0.08	-0.54	Seattle Genetics EPS beats by $3.26, beats on revenue [10/29/2020 4:10 PM]	166.42	-25.92 (-13.48%)	179.00	-13.34 (-6.94%)	90.57 - 213.94	2,756,837	557,773	6,628

30-07-2020	AH	4:00 PM ET (Jul 30)	SGEN	Seattle Genetics, Inc.	29,660	-0.54	-0.58	-0.24	Seattle Genetics EPS beats by $0.48, beats on revenue [7/30/2020 4:17 PM]	163.24	-7.90 (-4.62%)	166.65	-4.49 (-2.62%)	65.44 - 187.98	1,266,993	1,097,335	968